Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Views & Analysis
Brexit tweet

UK’s drug supply contingency plan for hard Brexit

The UK government has issued several documents to help businesses in planning for the eventuality of a no-deal Brexit, but the UK’s Brexit Health Alliance says “the guidance is a first step

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. MSD, Moderna skin cancer vaccine scores historic phase 3 win
  2. Trump taps White House aide Heidi Overton to lead FDA
  3. Sandoz adds 10 biosimilars through $322m Henlius deal
  4. Claude Science outperforms experts in protein binder task
  5. Sanofi to lay off 229 Blueprint employees, close offices

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more